The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Sorafenib versus hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma: A Japanese multi-center large cohort study.
 
Sadahisa Ogasawara
Honoraria - Bayer; Eisai
Consulting or Advisory Role - Bayer; Eisai
 
Kazuomi Ueshima
Honoraria - Bayer
Consulting or Advisory Role - Eisai
 
Masafumi Ikeda
Honoraria - Abbott Japan; Bayer Yakuhin; Bristol-Myers Squibb Japan; Dainippon Sumitomo Pharma; Eisai; Lilly Japan; Nobelpharma; Novartis; Otsuka; Taiho Pharmaceutical; Teijin Pharma; Yakult Honsha
Consulting or Advisory Role - Bayer Yakuhin; Daiichi Sankyo; Eisai; Kyowa Hakko Kirin; Lilly Japan; MSD; NanoCarrier; Novartis; Shire; Teijin Pharma
Research Funding - ASLAN Pharmaceuticals; AstraZeneca; Baxalta/Shire; Bayer Yakuhin; Bristol-Myers Squibb; Chugai Pharma; Eisai; Kowa; Kyowa Hakko Kirin; Lilly Japan; Merck Serono; MSD; NanoCarrier; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical; Takara Bio; Yakult Pharmaceutical
 
Yutaka Yasui
Speakers' Bureau - Bayer Yakuhin
 
Takeshi Terashima
Research Funding - Bayer (Inst); Eisai (Inst)
 
Tatsuya Yamashita
Speakers' Bureau - Bayer; Eisai
 
Shuntaro Obi
No Relationships to Disclose
 
Shinpei Sato
No Relationships to Disclose
 
Hiroshi Aikata
No Relationships to Disclose
 
Takumi Ohmura
Honoraria - Bayer; Eisai
Speakers' Bureau - Bayer
 
Hidekatsu Kuroda
No Relationships to Disclose
 
Takamasa Ohki
Speakers' Bureau - Abbvie; Bayer; Dainippon Sumitomo Pharma; Eisai; Otsuka; Shionogi
 
Kengo Nagashima
Consulting or Advisory Role - Fujimoto; Senju Pharmaceutical
 
Masayuki Kurosaki
Speakers' Bureau - Bayer; Eisai
 
Kazuaki Chayama
Consulting or Advisory Role - AbbVie; Asuka Seiyaku; GlaxoSmithKline
Speakers' Bureau - Abbott/AbbVie; Abbvie; Astellas Pharma; Bayer; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Dainippon Sumitomo Pharma; Eisai; Gilead Sciences; JIMRO; Mitsubishi Tanabe Pharma; MSD; Olympus Medical Systems; Otsuka; Pfizer; Taisho Toyama Pharma; Takeda; Zeria Pharmaceutical
 
Shuichi Kaneko
Consulting or Advisory Role - Bayer; Eisai
Speakers' Bureau - Bayer; Eisai
Research Funding - Bayer; Eisai
 
Namiki Izumi
Speakers' Bureau - Bayer; Eisai
 
Naoya Kato
Honoraria - Abbvie; Bayer; Bristol-Myers Squibb; Daiichi Sankyo; Dainippon Sumitomo Pharma; Eisai; Gilead Sciences; MSD; Otsuka; Takeda Science Foundation
Research Funding - Abbvie (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); Otsuka (Inst); Takeda (Inst)
 
Masatoshi Kudo
Honoraria - Abbvie; Bayer; Bristol-Myers Squibb Japan; EA Pharma; Eisai; Gilead Sciences; Merck Serono; Merck Serono; MSD; Novartis; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Eisai; MSD
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Otsuka (Inst); Taiho Pharmaceutical (Inst)
 
Masao Omata
Honoraria - Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Merck Sharp & Dohme; Mitsubishi Tanabe Pharma; Mochida Pharmaceutical Co. Ltd.; Sumitomo Dainippon
Consulting or Advisory Role - Gilead Sciences
Research Funding - Bayer (Inst)